BELGRADE, Mont., Jan. 09, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a worldwide medical expertise firm targeted on surgical options for the therapy of spinal problems, at this time introduced the appointment of Mark Schallenberger as Chief Operations Officer, efficient January 16, 2023.
“We’re thrilled to have Mark rejoin the workforce as we reinvent Xtant,” mentioned Sean Browne, President and Chief Govt Officer of Xtant Medical. “On this newly created function, Mark will drive the modernization of our manufacturing, lead the optimization of our processes and operations, and assist the diversification and improvement of latest product strains. We look ahead to Mark’s contributions to our key progress pillars.”
“I’m excited to be rejoining Xtant Medical on this new function,” mentioned Mark Schallenberger. “The Firm is well-positioned to speculate and construct upon the event of its modern and business main orthobiologics. I look ahead to working with the management workforce to drive higher operational efficiencies and generate worthwhile progress.”
Mr. Schallenberger has greater than 12 years of orthobiologics expertise targeted on product improvement and scientific affairs, having most lately served as Chief Operations Officer at Surgenex, a medical expertise producer, since June 2019. Beforehand, he served as Senior Director of Advertising and marketing and Product Improvement at DCI Donor Providers Tissue Financial institution, starting in February 2016. Earlier than that, Mr. Schallenberger served in varied roles with growing accountability from September 2010 to February 2016 culminating with Director of Scientific Affairs with Xtant Medical, previously Bacterin Worldwide Holdings. Mr. Schallenberger holds a Grasp of Science in Chemical Biology from The Scripps Analysis Institute and a Bachelor of Science diploma in Chemistry from the College of Montana.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a worldwide medical expertise firm targeted on the design, improvement, and commercialization of a complete portfolio of orthobiologics and spinal implant techniques to facilitate spinal fusion in advanced spine, deformity and degenerative procedures. Xtant individuals are devoted and gifted, working with the very best integrity to serve our prospects.
The symbols ™ and ® denote emblems and registered emblems of Xtant Medical Holdings, Inc. or its associates, registered as indicated in america, and in different nations. All different emblems and commerce names referred to on this launch are the property of their respective house owners.
Cautionary Assertion Concerning Ahead-Wanting Statements
This press launch accommodates forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements embody statements which might be predictive in nature, that depend on or discuss with future occasions or situations, or that embody phrases equivalent to “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “proceed,” “future,” ‘‘will,’’ “potential,” “going ahead,” comparable expressions or the adverse thereof, and the usage of future dates. Ahead-looking statements on this launch embody the Firm’s expectations concerning its future progress technique. The Firm cautions that its forward-looking statements by their nature contain dangers and uncertainties, and precise outcomes might differ materially relying on quite a lot of essential elements, together with, amongst others: the Firm’s future working outcomes and monetary efficiency; the flexibility to extend or preserve income; doable future impairment costs to long-lived belongings and goodwill and write-downs of extra stock if revenues proceed to lower; the flexibility to stay aggressive; the flexibility to innovate, develop and introduce new merchandise; the flexibility to interact and retain new and present impartial distributors and brokers and certified personnel and the Firm’s dependence on key impartial brokers for a good portion of its income; the impact of the COVID-19 pandemic and labor and staffing shortages on the Firm’s enterprise, working outcomes and monetary situation, particularly after they have an effect on key markets; the Firm’s capacity to implement efficiently its future progress initiatives and dangers related therewith; the impact of inflation, elevated rates of interest and different recessionary indicators and provide chain disruptions; the impact of product gross sales combine adjustments on the Firm’s monetary outcomes; authorities and third-party protection and reimbursement for Firm merchandise; the flexibility to acquire and preserve regulatory approvals and adjust to authorities laws; the impact of product legal responsibility claims and different litigation to which the Firm could also be topic; the impact of product recollects and defects; the flexibility to acquire and shield Firm mental property and proprietary rights and function with out infringing the rights of others; the flexibility to service Firm debt, adjust to its debt covenants and entry extra indebtedness; the flexibility to acquire extra financing on favorable phrases or in any respect; and different elements. Extra danger elements are contained within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2021 filed with the Securities and Trade Fee (SEC) on March 8, 2022 and subsequent SEC filings by the Firm. Buyers are inspired to learn the Firm’s filings with the SEC, out there at www.sec.gov, for a dialogue of those and different dangers and uncertainties. The Firm undertakes no obligation to launch publicly any revisions to any forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the prevalence of unanticipated occasions, besides as required by legislation. All forward-looking statements attributable to the Firm or individuals performing on its behalf are expressly certified of their entirety by this cautionary assertion.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Electronic mail: david.carey@finnpartners.com
Discussion about this post